WO2024075784A1 - ニトロソ化反応を抑制する添加剤の選定方法及びニトロソ化合物の生成を抑制した製剤 - Google Patents
ニトロソ化反応を抑制する添加剤の選定方法及びニトロソ化合物の生成を抑制した製剤 Download PDFInfo
- Publication number
- WO2024075784A1 WO2024075784A1 PCT/JP2023/036247 JP2023036247W WO2024075784A1 WO 2024075784 A1 WO2024075784 A1 WO 2024075784A1 JP 2023036247 W JP2023036247 W JP 2023036247W WO 2024075784 A1 WO2024075784 A1 WO 2024075784A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- additive
- nitrosation reaction
- selecting
- additives
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Definitions
- One embodiment of the present invention relates to a method for selecting an additive that inhibits a nitrosation reaction, and in particular to a method for selecting an additive that inhibits a nitrosation reaction in a pharmaceutical composition or formulation for medical use.
- one embodiment of the present invention relates to a formulation that inhibits the formation of nitroso compounds, which contains an additive that inhibits a nitrosation reaction.
- Nitroso compounds are a general term for organic compounds that contain a nitroso group, and nitrosamines are a type of nitroso compound that are produced when amines are nitrosated (a nitroso group is added to the amine nitrogen) by a NOx source such as nitrous acid.
- NOx source such as nitrous acid.
- some pharmaceuticals have been found to contain nitrosamines, which are suspected to be carcinogenic, and this has led to calls for risk assessment and reduction measures for nitroso compounds in formulation development.
- the permissible limit values for nitroso compounds are stipulated by notifications issued by regulatory authorities (for example, Voluntary Inspection of the Risk of Nitrosamines Contaminating Pharmaceuticals dated October 8, 2021).
- Non-Patent Document 2 It has been suggested that nitrosation reactions can be inhibited by antioxidants (Non-Patent Document 2), but antioxidants cannot be used in cases where they accelerate the decomposition of active ingredients or cause the dissolution behavior to deviate from the target profile. For this reason, there has been a demand for new additives that inhibit nitrosation reactions as an alternative to antioxidants.
- One object of the present invention is to provide a method for selecting an additive that inhibits nitrosation reactions.
- one object of the present invention is to provide a formulation that inhibits the production of nitroso compounds, which contains an additive selected based on a selection method for an additive that inhibits a nitrosation reaction.
- a method for selecting an additive that inhibits a nitrosation reaction includes adding an amine source and a NOx source to an additive to generate nitroso compounds, quantifying the amount of the generated nitroso compounds, and evaluating the inhibitory effect of the additive on the nitrosation reaction based on the amount of the generated nitroso compounds.
- the additive containing the amine source and NOx source may be heated under sealed conditions to generate nitroso compounds.
- the amine source may be a secondary amine, a tertiary amine or a quaternary amine.
- the NOx source may be one selected from the group consisting of nitrous acid, nitrite ion, nitrite salts, nitric acid, nitrates, nitrous acid ions, nitrite esters, peroxynitrite, nitrosonium ions, nitro compounds, anhydrous nitrous acid, dinitrogen tetroxide, nitrosyl halides, nitrosyl thiocyanates, nitrosophenols, nitrosothiols, aqua regia, nitric oxide, nitrogen dioxide, and nitrile chloride.
- a formulation is provided that contains one or more additives selected by any of the methods for selecting an additive that inhibits a nitrosation reaction described above.
- the one or more additives may be selected from the group consisting of sodium stearyl fumarate, magnesium oxide, dry methacrylic acid copolymer LD, macrogol 6000, pregelatinized starch, carmellose, aspartame, crospovidone, microcrystalline cellulose, acesulfame potassium, calcium stearate, Kollicoat IR, polyvinyl alcohol, croscarmellose sodium, sodium starch glycolate, carmellose calcium, magnesium stearate, and hydroxypropyl cellulose.
- the one or more additives may be selected from the group consisting of sodium stearyl fumarate, magnesium oxide, dry methacrylic acid copolymer LD, macrogol 6000, pregelatinized starch, carmellose, aspartame, crospovidone, microcrystalline cellulose, and acesulfame potassium.
- the one or more additives may be selected from the group consisting of magnesium oxide, dry methacrylic acid copolymer LD, pregelatinized starch, carmellose, and aspartame.
- a method for selecting an additive that inhibits a nitrosation reaction is provided.
- a formulation that inhibits the production of nitroso compounds is provided, which contains an additive selected based on the method for selecting an additive that inhibits a nitrosation reaction.
- FIG. 1 is a flow diagram showing a method for selecting an additive that inhibits a nitrosation reaction according to one embodiment of the present invention.
- FIG. 1 shows the amounts of NDLRT produced when the preparations of Example 33, Comparative Example 3, and Reference Example 5 were stored at 40° C. and 75% RH for 4 weeks.
- FIG. 1 shows the amounts of NDLRT produced when the preparations of Example 33, Comparative Example 3, and Reference Example 5 were stored at 25° C. and 55% RH for 3 weeks.
- nitroso compound is a general term for compounds having a nitroso group represented by the following chemical formula 1.
- nitroso compound is a general term for compounds having a structure in which a nitroso group is added to the nitrogen of an amine, amide, or the like.
- Nitroso compounds include N-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), N,N'-dinitrosopentamethylenetetramine (DPT), N-nitrosomethylethylamine (NMEA), N-nitrosopiperidine (NPIP), N-nitrosopyrrolidine (NPYR), N-nitrosomorpholine (NMOR), N-nitrosoproline (NPRO), and N- Examples include, but are not limited to, nitrososarcosine (NSAR), N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), N-nitrosomethylphenylamine (NMPA), N-nitrosodiisopropylamine (NDIPA), N-nitrosoethylisoprop
- NDMA, NDEA, NMPA, NDIPA, NEIPA, NDBA, and NMBA are nitroso compounds that may be present as impurities in drug substances and pharmaceutical products, as listed in Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry, February 2021, Revision 1.
- NOx source is a general term for compounds containing a nitroso group that can generate a nitroso compound by reacting with an amine source.
- NOx is synonymous with nitrogen oxides.
- examples of NOx sources include, in addition to nitrous acid, nitrite ions, and nitrite salts, nitric acid and nitrate salts, nitrous acid ions, nitrite esters, peroxynitrite salts, nitrosonium ions, nitro compounds, anhydrous nitrous acid, dinitrogen tetroxide, nitrosyl halides, nitrosyl thiocyanates, nitrosophenols, nitrosothiols, aqua regia, nitric oxide, nitrogen dioxide, and nitrile chloride, but are not limited to these.
- amine source is a general term for an amine compound capable of generating a nitroso compound by reacting with a NOx source.
- the amine source also includes compounds that undergo nitrosation, such as urea compounds and amide compounds.
- a secondary amine, tertiary amine, or quaternary amine can be used as the amine source. Since the reactivity to the NOx source differs depending on the amine source, it is preferable to use an amine source that contributes to the generation of the nitroso compound to be measured.
- if the drug substance to be added thereto is used as the amine source, it is possible to more accurately select an additive that suppresses the nitrosation reaction of the drug substance.
- the inventors have discovered that since drug substances having a secondary amine or tertiary amine skeleton in their structure may generate nitroso compounds during the formulation process, it is possible to reduce the number of nitroso compounds in a pharmaceutical composition or formulation by using an additive that inhibits the nitrosation reaction in combination with the drug substance.
- a pharma- ceutical acceptable additive is used as the measurement sample, but the present invention is not limited thereto, and can also be used as a method for evaluating the inhibitory effect of a food additive on a nitrosation reaction.
- FIG. 1 is a flow diagram showing a method for selecting an additive that suppresses a nitrosation reaction according to this embodiment.
- the additive is brought into contact with an amine source and a NOx source to generate a nitroso compound (step S11).
- the additive to be evaluated, the amine source, and the NOx source are added to a sealable container and mixed, and the amine source and NOx source are brought into contact with the additive.
- Step S12 The additive that has been in contact with the amine source and NOx source is heated under sealed conditions to generate nitroso compounds.
- sealed conditions refers to a state in which the mixture is sealed in a sealed container, or a state in which a container containing the mixture is tightly sealed.
- the mixture of the additive, the amine source, and the NOx source is stored under sealed conditions in a thermostatic chamber at 40°C and 75% relative humidity (75% RH).
- the storage period is, for example, 2 days, 3 days, 1 week, 2 weeks, or 4 weeks.
- An appropriate solvent is added to the mixture that has been stored for a specified period of time to extract the nitroso compounds.
- a solid-liquid separation means such as a filter is used to remove solid components such as additives from the extract to obtain a sample solution (step S13).
- the solvent can be appropriately selected from those that can dissolve the nitroso compounds and do not affect the quantification of the nitroso compounds.
- a water/methanol mixture (7:3) can be used.
- the amount of nitroso compounds in the sample solution is quantified (step S14).
- a liquid chromatography tandem mass spectrometer LC-MS/MS
- the method for quantifying the amount of nitroso compounds is not limited to LC-MS/MS.
- the quantified amount of nitroso compounds produced can be associated with the additives used and stored in a database (step S15).
- the amount of nitroso compounds produced is compared to evaluate the effect of each additive in inhibiting the production of nitroso compounds (step S16).
- the amount of nitroso compounds in a pharmaceutical composition or formulation can be reduced to below the allowable limit by selecting the type and amount of additives to be added to the pharmaceutical composition or formulation from pharma- ceutically acceptable additives suitable for achieving the quality standards required for pharmaceuticals, such as the dissolution or chemical stability of the drug substance, or the disintegration or hardness of tablets, using the amount of nitroso compounds generated as an indicator.
- the antioxidant is known to have the effect of suppressing the formation of nitroso compounds, and can be used in combination with one or more additives selected by the method for selecting an additive that suppresses the nitrosation reaction.
- the type and amount of additives used in tablets have been adjusted to control the dissolution or chemical stability of the active ingredient, or the disintegration or hardness of the tablets, but it has been difficult to control the amount of nitroso compounds generated in the tablets.
- the formulation examination method according to this embodiment it is possible to obtain the desired characteristics while keeping the amount of nitroso compounds generated in pharmaceutical compositions and formulations below the allowable limit.
- additives capable of reducing the production of nitroso compounds include additives selected from the group consisting of sodium stearyl fumarate, magnesium oxide, dry methacrylic acid copolymer LD, macrogol 6000, pregelatinized starch, carmellose, aspartame, crospovidone, crystalline cellulose, acesulfame potassium, calcium stearate, Kollicoat IR, polyvinyl alcohol, croscarmellose sodium, sodium starch glycolate, carmellose calcium, magnesium stearate, and hydroxypropyl cellulose.
- the additive capable of reducing the generation of nitroso compounds is preferably an additive selected from the group consisting of sodium stearyl fumarate, magnesium oxide, dry methacrylic acid copolymer LD, macrogol 6000, pregelatinized starch, carmellose, aspartame, crospovidone, crystalline cellulose, and acesulfame potassium.
- the additive capable of reducing the generation of nitroso compounds is preferably an additive selected from the group consisting of magnesium oxide, dry methacrylic acid copolymer LD, pregelatinized starch, carmellose, and aspartame.
- a pharmaceutical composition or preparation that suppresses the generation of nitroso compounds can be obtained.
- pharmaceutical composition refers to a mixture of a drug substance and one or more pharma- ceutical acceptable additives.
- preparation refers to a dosage form such as a granule or dry syrup obtained by granulating the pharmaceutical composition, an injection in which the pharmaceutical composition is dissolved in a pharma- ceutical acceptable solvent, a tablet obtained by compressing the pharmaceutical composition, or a capsule in which the pharmaceutical composition is encapsulated.
- a powder in which the pharmaceutical composition is used as it is is also included in the formulation.
- the formulation according to this embodiment includes a pharmaceutical composition containing a drug substance and one or more additives selected by a method for selecting an additive that inhibits a nitrosation reaction.
- the formulation according to this embodiment contains a drug substance and one or more selected additives in an amount and combination that is equal to or less than the allowable limit of nitroso compounds.
- the solvent used in producing the pharmaceutical composition or formulation is preferably selected from solvents evaluated by the above-mentioned method for selecting an additive that inhibits the nitrosation reaction, and more preferably selected from solvents that generate a small amount of nitroso compounds.
- the formulation can be manufactured by direct compression, in which the drug substance and one or more selected additives are mixed and compressed to suppress the nitrosation reaction, or by dry granulation.
- ⁇ Test solution> 5.25 g of citric acid monohydrate was dissolved in water to prepare 1000 ml of citric acid aqueous solution. 1000 ml of 0.05 mol/l disodium hydrogen phosphate test solution was prepared, and the citric acid aqueous solution was added to adjust the pH to 4.0 to obtain a test solution (pH 4.0).
- NDMA N-nitrosodimethylamine
- Examples 1 to 15, Comparative Example 1, Reference Examples 1 to 2 Each additive to be measured and lactose hydrate were weighed out in a headspace vial so that the mixing ratio was 500 mg as shown in Table 1. 20 ⁇ l of reaction solution (dimethylamine 480 mmol/l, sodium nitrite 137 mmol/l, diluted with test solution (pH 4.0)) was added. The headspace vial was sealed and stored in a thermo-hygrostat (40°C, 75% RH) for 88 hours.
- Reference Examples 1 and 2 are antioxidants.
- LC/MS/MS (LC: Nexera (registered trademark) X2 (Shimadzu Corporation), MS/MS: QTRAP5500 triple quadrupole mass spectrometer (AB Sciex Corporation))
- Mobile phase A 0.1% formic acid - 5 mM ammonium formate solution
- Mobile phase B 0.1% formic acid - 5 mM ammonium formate methanol
- Column temperature constant temperature around 40°C
- the amount of NDMA contained in each sample solution was measured under the above measurement conditions.
- the amount of NDMA in the reference lactose hydrate 200M was set as 100%, and the production ratio of the amount of NDMA contained in each sample solution was calculated.
- the calculated production ratio of NDMA for each additive is shown in Table 1. Note that ND in the table indicates that it is below the detection limit. Note that the detection limit is 0.96 ng/ml.
- NDMA nitrosodimethylamine
- NDLRT nitrosodesloratadine
- the results in Table 2 show that the additives of Examples 16 to 32 suppressed the formation of nitrosamines more than the additive of Comparative Example 2.
- the additives of Examples 16 to 25 also suppressed the formation of nitrosamines by 50% or more more than the additive of Comparative Example 2.
- the additives of Examples 17, 18, 20, 21 and 22 suppressed the formation of nitrosamines by 70% or more more than the additive of Comparative Example 2.
- the nitrosamine formation suppression effect of the additives of Examples 17, 18, 20, 21 and 22 was comparable to that of the antioxidants of Reference Examples 3 and 4, making it clear that they can be used as nitrosamine formation suppression additives to replace antioxidants.
- Example 33 Comparative Example 3, Reference Example 5
- the nitrosamine production inhibitory effect of each additive was evaluated, but in Example 33, Comparative Example 3, and Reference Example 5, the nitrosamine production inhibitory effect of a formulation was evaluated.
- Desloratadine and various additives were weighed, mixed, and sieved to obtain a mixture so that the blending amount in one tablet was as shown in Table 3 below.
- Example 33 The formulations of Example 33, Comparative Example 3, and Reference Example 5 were sealed and stored in a thermo-hygrostat at 25°C and 55% RH for 3 weeks or at 40°C and 75% RH for 4 weeks.
- NDLRT nitrosodesloratadine
- carmellose which was found to have an inhibitory effect on nitrosation reactions in Examples 5 and 21, was found to have an inhibitory effect on nitrosation reactions in the formulation to the same extent as the antioxidant in Reference Example 5.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23874909.7A EP4600642A1 (en) | 2022-10-05 | 2023-10-04 | Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound |
| JP2024555838A JPWO2024075784A1 (cg-RX-API-DMAC7.html) | 2022-10-05 | 2023-10-04 | |
| US19/170,434 US20250255965A1 (en) | 2022-10-05 | 2025-04-04 | Method for selecting additive for suppressing nitrosation reaction, and formulation for suppressing generation of nitroso compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263413310P | 2022-10-05 | 2022-10-05 | |
| US63/413,310 | 2022-10-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/170,434 Continuation US20250255965A1 (en) | 2022-10-05 | 2025-04-04 | Method for selecting additive for suppressing nitrosation reaction, and formulation for suppressing generation of nitroso compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024075784A1 true WO2024075784A1 (ja) | 2024-04-11 |
Family
ID=90608075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/036247 Ceased WO2024075784A1 (ja) | 2022-10-05 | 2023-10-04 | ニトロソ化反応を抑制する添加剤の選定方法及びニトロソ化合物の生成を抑制した製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250255965A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4600642A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024075784A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024075784A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025225724A1 (ja) * | 2024-04-26 | 2025-10-30 | 東和薬品株式会社 | 医薬原材料または医薬におけるニトロソ化合物の生成を低減する方法 |
| JP2025168321A (ja) * | 2024-04-26 | 2025-11-07 | 東和薬品株式会社 | 医薬原材料または医薬におけるニトロソ化合物の生成を低減する方法 |
| JP2026116143A (ja) * | 2024-12-27 | 2026-07-09 | 東和薬品株式会社 | フィルターおよびその適用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005261320A (ja) * | 2004-03-19 | 2005-09-29 | National Institute Of Advanced Industrial & Technology | キトサンを有効成分とする亜硝酸系化合物のスカベンジャー |
| WO2022069894A1 (en) * | 2020-10-01 | 2022-04-07 | Betagenon Bio Ab | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
-
2023
- 2023-10-04 JP JP2024555838A patent/JPWO2024075784A1/ja active Pending
- 2023-10-04 WO PCT/JP2023/036247 patent/WO2024075784A1/ja not_active Ceased
- 2023-10-04 EP EP23874909.7A patent/EP4600642A1/en active Pending
-
2025
- 2025-04-04 US US19/170,434 patent/US20250255965A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005261320A (ja) * | 2004-03-19 | 2005-09-29 | National Institute Of Advanced Industrial & Technology | キトサンを有効成分とする亜硝酸系化合物のスカベンジャー |
| WO2022069894A1 (en) * | 2020-10-01 | 2022-04-07 | Betagenon Bio Ab | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Non-Patent Citations (10)
| Title |
|---|
| CONTROL OF NITROSAMINE IMPURITIES IN HUMAN DRUGS, GUIDANCE FOR INDUSTRY, February 2021 (2021-02-01) |
| EMILIA IGLESIAS: "Differences in the activity of neutral and ionized β-cyclodextrin on the nitrosation of amines by phenylpropyl nitrites", NEW JOURNAL OF CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 24, no. 12, 1 January 2000 (2000-01-01), GB , pages 1025 - 1035, XP093156525, ISSN: 1144-0546, DOI: 10.1039/b005647m * |
| JIREŠ JAKUB; DOUŠA MICHAL: "Nitrites as precursors of N-nitrosation in pharmaceutical samples – A trace level analysis", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, ELSEVIER B.V., AMSTERDAM, NL, vol. 213, 18 February 2022 (2022-02-18), AMSTERDAM, NL , XP087011676, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2022.114677 * |
| NANDA KAUSIK K., TIGNOR STEVEN, CLANCY JAMES, MAROTA MELANIE J., ALLAIN LEONARDO R., D'ADDIO SUZANNE M.: "Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 110, no. 12, 1 December 2021 (2021-12-01), US , pages 3773 - 3775, XP093146433, ISSN: 0022-3549, DOI: 10.1016/j.xphs.2021.08.010 * |
| NANDA, K. ET AL.: "Inhibition of N-Nitrosamine Formation in Drug Product: A Model Study", J. PHARM. SCI., vol. 110, 2021, pages 3773 - 3775, XP093146433, DOI: 10.1016/j.xphs.2021.08.010 |
| RICARDA LEISTER: "Reducing the risk of nitrosoamine formation in pharmaceuticals: the role of pharmaceutical additives", 15 August 2023 (2023-08-15), pages 1 - 12, XP093156532, Retrieved from the Internet <URL:https://meggle.co.jp/wordpress/wp-content/uploads/2023/08/%E5%8C%BB%E8%96%AC%E5%93%81%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%83%8B%E3%83%88%E3%83%AD%E3%82%BD%E3%82%A2%E3%83%9F%E3%83%B3%E9%A1%9E%E7%94%9F%E6%88%90%E3%81%AE-%E3%83%AA%E3%82%B9%E3%82%AF%E8%BB%BD%E6%B8%9B%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6_%E5%8C%BB%E8%96%AC%E5%93%81%E6%B7%BB%E5%8A%A0%E5%89%A4%E3%81%AE%E5%BD%B9%E5%89%B2-1.pdf> * |
| TANIMURA. AKIO: "Possibility of in-vivo production of N-ilsanthoron compounds through the reaction between pharmaceuticals and nitrites", EISI SHIKENJO HOKOKU - BULLETIN OF NATIONAL INSTITUTE OF HYGIENIC SCIENCES, KOSEI-SHO KOKURITSU WISEI SHIKENJO, TOKYO,, JP, vol. 99, no. 56, 1 January 1981 (1981-01-01), JP , pages 1 - 16, XP009553789, ISSN: 0077-4715 * |
| TORGNY RUNDLOF: "Potential Nitrite Scavengers as Inhibitors of the Formation of N-Nitrosamines in Solution and Tobacco Matrix Systems", J. AGRIC. FOOD CHEM., vol. 48, no. 9, 1 January 2000 (2000-01-01), pages 4381 - 4388, XP093156512 * |
| VOLUNTARY INSPECTION ON RISK OF NITROSAMINES CONTAMINATION IN PHARMACEUTICAL PREPARATIONS, 8 October 2021 (2021-10-08) |
| VOLUNTARY INSPECTION ON THE RISK OF NITROSAMINES CONTAMINATION IN PHARMACEUTICAL PREPARATIONS, 8 October 2021 (2021-10-08) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025225724A1 (ja) * | 2024-04-26 | 2025-10-30 | 東和薬品株式会社 | 医薬原材料または医薬におけるニトロソ化合物の生成を低減する方法 |
| JP2025168321A (ja) * | 2024-04-26 | 2025-11-07 | 東和薬品株式会社 | 医薬原材料または医薬におけるニトロソ化合物の生成を低減する方法 |
| JP2026116143A (ja) * | 2024-12-27 | 2026-07-09 | 東和薬品株式会社 | フィルターおよびその適用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250255965A1 (en) | 2025-08-14 |
| JPWO2024075784A1 (cg-RX-API-DMAC7.html) | 2024-04-11 |
| EP4600642A1 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4600642A1 (en) | Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound | |
| EP4600641A1 (en) | Method for quantifying reactive nox, and formulation for suppressing generation of nitroso compounds | |
| US11938131B2 (en) | Stable pharmaceutical composition for oral administration | |
| EP3513788B1 (en) | Solid preparation containing colorant | |
| EP2990038B1 (en) | Solid pharmaceutical composition | |
| EP4454703A2 (en) | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same | |
| EP2826477B1 (en) | Solid composition of amino carboxylate salt | |
| WO2023012376A2 (en) | Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds | |
| EP4169516A1 (en) | Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds | |
| EP3272345B1 (en) | Solid preparation containing antioxidant agent | |
| WO2024165666A1 (en) | Method of reducing the amount of n-nitrosamine impurities | |
| JPWO2010110436A1 (ja) | 塩基性添加剤を含有するマトリックス型徐放性製剤 | |
| KR101915056B1 (ko) | 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법 | |
| CN120713883B (zh) | 一种改善稳定性的布美他尼口服固体制剂及其制备方法 | |
| US20230056424A1 (en) | Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds | |
| CN103709170A (zh) | 降血糖的药用原料药 | |
| CN102895201B (zh) | 丙戊酸半钠片剂及其制备方法 | |
| EP2117534B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
| EP2730279B1 (en) | Immediate release formulations of cinacalcet | |
| CN103694245A (zh) | 降糖药用原料药 | |
| JP2026510553A (ja) | シチシンを含む医薬組成物 | |
| AU2021105843A4 (en) | A method to enhance solubility of glimepiride | |
| WO2025219830A1 (en) | Pharmaceutical compositions of ribociclib | |
| CN120131660A (zh) | 一种组合物及其应用 | |
| WO2025132869A1 (en) | Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23874909 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024555838 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202517042347 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023874909 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2023874909 Country of ref document: EP Effective date: 20250506 |
|
| WWP | Wipo information: published in national office |
Ref document number: 202517042347 Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023874909 Country of ref document: EP |